StockData
LivaNova PLC logo

LivaNova PLC (LIVN) stock analysis

LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 13/3032% above fair value
$91.92−0.52 (-0.56%)

Close on Nov 17, 2026Market cap $5.06BP/E 27.1Yield –

StockData Score

Prices as of Nov 17, 2026How the score works

Value0Growth4Performance4Health5Dividend0

Mixed13 of 30 checks passed

LivaNova passes 13 of the 30 checks behind our score; 9 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
4/6
Past performance
4/6
Financial health
5/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 18.2%, above the 10% that usually covers the cost of capital.

  • Low debt

    Debt is 22.1% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 10.8% a year over the last three fiscal years.

  • Interest well covered

    Operating income covers interest expense 5.0 times.

What to watch

  • Margin of safety under 20%

    The price is 32.0% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $91.92 is above our fair value estimate of $69.65.

  • Return on equity under 15%

    Return on equity was 15.4% over the last twelve months and averaged -6.2% over five years; we look for 15% on both.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.71; above 3 is the safe zone and below 1.8 the distress zone.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    LivaNova's P/E of 27.1 is above the Surgical, Medical, and Dental Instruments and Supplies median of 27.0.

  • EV/EBITDA above its 5-year median

    LivaNova's EV/EBITDA of 25.8 is above its 5-year median of 19.3.

  • P/B above the industry

    LivaNova's price-to-book of 3.82 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.31.

  • Trading above fair value

    The share price of $91.92 is above our fair value estimate of $69.65.

  • Margin of safety under 20%

    The price is 32.0% above fair value, so there is no margin of safety.

Growth4/6
  • Revenue growing 10%+ a year

    Revenue grew 10.8% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 12.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 10.4%.

  • Guidance raised

    LivaNova raised its full-year 2026 revenue outlook on Aug 5, 2026.

  • Gross margin improving

    Gross margin was 68.1% over the last twelve months, against 68.0% a year earlier.

Past performance4/6
  • Return on equity under 15%

    Return on equity was 15.4% over the last twelve months and averaged -6.2% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 18.2%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    LivaNova's return on equity of 15.4% is above the Surgical, Medical, and Dental Instruments and Supplies median of -35.2%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 12.8% over the last twelve months, against a 5-year average of -6.5%.

  • Net margin above the industry

    LivaNova's net margin of 12.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.8%.

Financial health5/6
  • Low debt

    Debt is 22.1% of shareholders' equity, under the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 59.1% five years ago to 22.1%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 84.9% of total debt.

  • Interest well covered

    Operating income covers interest expense 5.0 times.

  • Short-term assets cover short-term debts

    Current assets are 1.45 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.71; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    LivaNova has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$69.65

The share price is 32% above this estimate.

20%+ below
Near fair value
20%+ above
$91.92Price$69.65Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E27.0×–27.0×$91.6540%
EV/EBITDA17.8×19.3×16.3×$64.7235%
P/B2.9×2.4×3.3×$69.2010%
Earnings power9.3% cost of equity––$22.8115%
Fair value$69.65100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Surgical, Medical, and Dental Instruments and Supplies median 27.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$61.52M
Value traded per 1% price move
$39.68M

Downside

Low risk

Typical loss in a bad month
10.0%
Volatility (annualized)
39%
Sharpe ratio, 1 year
1.57
Beta to the S&P 500 (5Y)
0.83

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2025

Gross margin

67.7%+4.0 pts over 5 years

Operating margin

14.4%+43.7 pts over 5 years

Net margin

-17.5%+19.9 pts over 5 years

See a number that looks wrong?